OVERVIEW

Community Practice Connections: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of Immunotherapy is organized by Physicians' Education Resource LLC (PER) and will be held from Aug 13, 2018 - Aug 13, 2019.

The target audience for this medical event is directed toward medical oncologists. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cSCC are also invited to participate, as well as those involved in the multidisciplinary care of patients with cSCC, including dermatologists, surgeons, head and neck cancer surgeons, and Mohs surgeons. This CME Conference has been approved for a maximum of 1.5 Credits.

Description:
Although most cases of cutaneous squamous cell carcinoma (cSCC) are diagnosed early and cured with office-based therapy, advanced cases of cSCC harbor a significant morbidity and mortality risk, and have few available treatment options outside of clinical trials. In this online activity, focused on expert interviews and clinical vignettes, you will engage with renowned medical experts in the treatment of cSCC, Omid Hamid, MD, Jason J. Luke, MD, Nikhil I. Khushalani, MD, and Chrysalyne Schmults, MD, MSCE; gain insight into staging and sequencing options; and consider how emerging immunotherapy options will impact the treatment paradigm. The content and interviews are based on presentations delivered in June 2018 at the New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of Immunotherapy meeting held adjunct to the 2018 American Society of Clinical Oncology Annual Meeting.

For busy oncologists focused on the management of complex patients with advanced or metastatic cSCC, this activity provides you with an up-to-date perspective on the efficacy and safety evidence underpinning the use of immunotherapy for this patient population.

Below are some clinical pearls and highlights from the activity:
• Risk factors for the development of cSCC include cumulative sun exposure and immunosuppression status. Immunotherapy holds promise of therapeutic benefit for most patients; however, further research is needed to determine appropriate therapies for patients who are immunosuppressed.
• Emerging evidence shows that immunotherapy treatment for patients with cSCC is associated with objective response rates between 40% and 50%, along with tolerable safety profiles. Expected US Food and Drug Administration approval is eagerly awaited by oncologists.
• Treatment with immune checkpoint inhibitors provides survival benefits, but associated toxicities need to be carefully managed. Upfront educational efforts with both patients and family caregivers may encourage prompt and effective management of immune-related adverse events.

Learning Objectives:
At the conclusion of this activity, you should be better prepared to:
• Discuss current unmet clinical needs in the management of advanced/metastatic cSCC and evidence-based recommendations for the care of patients with these tumors
• Determine the rationale for development of cytoreductive strategies for the management of patients with advanced/metastatic cSCC
• Report recent evidence concerning the use of emerging immunotherapeutic approaches for the treatment of patients with advanced or metastatic cSCC
• Describe multidisciplinary approaches to plan for and proactively mitigate the impact of immune-related adverse events in patients who are undergoing treatment for advanced/metastatic cSCC